title: Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
authors.affiliation: Affiliations of authors: Eli Lilly and Company, Indianapolis, IN (LMH, GC, LB); Medical Decision Modeling, Inc., Indianapolis, IN (LS); Merck KGaA, Darmstadt, Germany (PvH); EMD Serono, Rockland, MA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Hess
authors.forename: Gebra
authors.initials: G
authors.lastname: Carter
authors.forename: Lee
authors.initials: L
authors.lastname: Smolen
authors.forename: Lee
authors.initials: L
authors.lastname: Bowman
authors.forename: Philipp
authors.initials: P
authors.lastname: von Hohnhorst
authors.forename: Chris
authors.initials: C
authors.lastname: Seagle
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D005820:Genetic Testing / Q000191:economics*; D006801:Humans; D008297:Male; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D018631:ras Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D048493:Proto-Oncogene Proteins B-raf; D018631:ras Proteins